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INTRODUCTION: A majority of patients with melanoma brain metastases develop multiple lesions, and these
patients show particularly poor prognosis. To develop improved treatment strategies, detailed insights into the
biology of melanoma brain metastases, and particularly the development of multiple lesions, are needed. The
purpose of this preclinical investigation was to study melanoma cell migration within the brain after cell injection
into a well-defined intracerebral site. METHODS: A-07, D-12, R-18, and U-25 human melanoma cells transfected
with green fluorescent protein were injected stereotactically into the right cerebral hemisphere of nude mice.
Moribund mice were killed and autopsied, and the brain was evaluated by fluorescence imaging or histological
examination. RESULTS: Intracerebral inoculation of melanoma cells produced multiple lesions involving all regions
of the brain, suggesting that the cells were able to migrate over substantial distances within the brain. Multiple
modes of transport were identified, and all transport modes were observed in all four melanoma lines. Thus, the
melanoma cells were passively transported via the flow of cerebrospinal fluid in the meninges and ventricles, they
migrated actively along leptomeningeal and brain parenchymal blood vessels, and they migrated actively along the
surfaces separating different brain compartments. CONCLUSION: Migration of melanoma cells after initial arrest,
extravasation, and growth at a single location within the brain may contribute significantly to the development of
multiple melanoma brain metastases.
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Brain metastasis is a frequent and fatal complication of malignant
melanoma, and 20% to 55% of patients with metastatic melanoma
die as a result of their brain metastases [1–3]. Melanoma brain
metastases are generally resistant to both radiation and chemotherapy,
and furthermore, they are characteristically multifocal and are
therefore difficult to treat with surgical resection [4]. Clinical studies
have reported that approximately 60% of melanoma patients
diagnosed with brain metastases develop multiple brain lesions, and
these patients show particularly poor prognosis [5–7]. To develop
improved treatment strategies for these patients, detailed insights into
the biology of melanoma brain metastases, and particularly the
development of multiple brain lesions, are highly needed.
Multiple brain metastases may arise from multiple tumor cells
entering the brain from the arterial circulation at different times and
at different locations within the brain. Alternatively, they may arise as
a result of tumor cell migration within the brain after initial arrest,
extravasation, and growth at a single location. Preclinical studies havedemonstrated that melanoma cells can be highly motile within the
brain and can migrate actively along the external surface of brain
microvessels [8–10]. Carbonell et al. have suggested that this type of
migration relies on β1 integrin-mediated tumor cell adhesion to the
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melanoma cells along brain microvessels has been observed in studies
of patient biopsies and autopsy specimens [11,12]. These data suggest
that migration of melanoma cells away from an original metastatic site
within the brain may contribute to the development of multiple brain
lesions in melanoma patients. However, most studies have detected
melanoma cell migration across relatively short distances within the
brain, and preclinical data are mainly derived from studies where
tumor cells were injected into the arterial circulation, thus making it
difficult to determine the origin of individual brain lesions.
In the study reported here, we injected human melanoma cells
transfected with green fluorescent protein (GFP) into a well-defined
site in the right cerebral hemisphere of nude mice by using a
stereotactic device. Moribund mice were killed and autopsied, and
melanoma cells within the brain were detected by GFP fluorescence
imaging or by GFP immunohistochemistry. Multiple melanoma
lesions involving brain regions far from the injection site were
detected, and we identified multiple modes of melanoma cell
transport within the brain.Figure 1. T2-weighted magnetic resonance (MR) images of the
mouse brain illustrating the cell inoculation site (cross) located 1
mm lateral to the sagittal suture lines and 3 mm caudal to the skull.
The images show a coronal (top) and a horizontal section (bottom),
and were recorded by using a 7.05-T Bruker small-animal MR
scanner and a fast spin echo pulse sequence with a repetition time
of 2200 milliseconds and an echo time of 36 milliseconds.Materials and Methods
Mice
Adult (8-10 weeks of age) female BALB/c nu/nu mice were used as
host animals. The mice were bred at our institute and maintained
under specific pathogen-free conditions at a temperature of 22°C to
24°C and a humidity of 30% to 50%. The animal experiments were
approved by the Institutional Committee on Research Animal Care
and were performed according to the Interdisciplinary Principles and
Guidelines for the Use of Animals in Research, Marketing, and
Education (New York Academy of Sciences, New York, NY).
Cell Lines
Intracerebral tumors were initiated from the A-07, D-12, R-18,
and U-25 human melanoma cell lines [13]. When these lines were
established, large stocks of cells were frozen and stored in liquid
nitrogen. Cells derived directly from the frozen stocks were
constitutively transfected with GFP by lipofection using the
pEGFP-N1 plasmid (Clontech Laboraories, Mountain View, CA)
as described elsewhere [14]. Frozen stocks of cell clones showing high
and stable GFP expression were established, and the GFP transfected
cell cultures used in the experiments described here were initiated
from these frozen stocks. Monolayer cultures were incubated at 37°C
in a humidified atmosphere of 5% CO2 in air and subcultured twice a
week in RPMI 1640 (25 mM HEPES and L-glutamine) medium.
The medium was supplemented with 13% bovine calf serum; 250
μg/ml of penicillin; 50 μg/ml of streptomycin; and 700 μg/ml
(A-07), 900 μg/ml (D-12), 2200 μg/ml (R-18), or 1200 μg/ml
(U-25) of genetecin. However, genetecin selection may not have been
necessary because we have revealed that the cells show high GFP
expression even when grown for 3 months in medium without
genetecin. By initiating new cell cultures from the frozen stocks at
regular short intervals, we ensured that the experiments were not
influenced by changes in the characteristics of the cell lines that may
be induced during long-term culture in vitro.
Anesthesia
Intracerebral injection of tumor cells was carried out with
anesthetized mice. Fentanyl citrate (Janssen Pharmaceutica, Beerse,Belgium), fluanisone (Janssen Pharmaceutica), and midazolam
(Hoffmann-La Roche, Basel, Switzerland) were administered intra-
peritoneally in doses of 0.63 mg/kg, 20 mg/kg, and 10 mg/kg,
respectively. The body core temperature of the mice was maintained
at 37°C to 38°C by using a heating pad.
Intracerebral Tumor Cell Inoculation
The mice were fixed in a stereotactic apparatus (Model 900; Kopf
Instruments, Tujunga, CA) for inoculation of tumor cells into the
right cerebral hemisphere. The injection point was 2 mm anterior to
the coronal and 1 mm lateral to the sagittal suture lines (Figure 1).
The immediate mouse mortality and the development of neurological
signs shortly after cell inoculation have been shown to be low by using
this injection point [15]. A 100-μl Hamilton syringe with a 26-gauge
needle was used to inject 3.0 × 103 tumor cells suspended in 6 μl of
Ca2+-free and Mg2+-free Hanks’ balanced salt solution at a depth of
3.0 mm below the skull. To minimize tumor cell reflux, the cells were
injected slowly, and the needle was left in place for 2 minutes before it
was retracted slowly, as suggested by Fidler [15]. Twenty mice of each
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daily for up to 70 days after tumor cell injection. Moribund mice were
killed and autopsied, and the brain was removed for subsequent
fluorescence imaging or histological analysis. The mice were defined
to be moribund when they showed a weight loss of 20% or when the
skull sutures were disconnected because of intracranial tumor growth.
Fluorescence Imaging
Imaging was performed with an inverted fluorescence microscope
equipped with a filter for green light (IX-71; Olympus, Munich,
Germany), a black-and-white CCD camera (C4742-95; HamamatsuFigure 2. Multiple brain lesions after intracerebral injection of GFP-e
GFP immunohistochemistry. (A) GFP fluorescence images of the cra
brain obtained 4 weeks after injection of R-18 cells. Dotted lines indic
injection site. (B) GFP-stained histological brain sections showing R-18
panel), and between the cerebellum and the brain stem (right panel). (
leptomeningeal linings of the right cerebral hemisphere (left panel), th
panel). Scale bars, 2 mm.Photonics, Hamamatsu, Japan), and appropriate image acquisition
software (Wasabi, Hamamatsu Photonics). The fresh brain was
imaged immediately after autopsy. The cranial and caudal surfaces of
the brain as well as three coronal brain sections with a thickness of ~2
mm were imaged at low (×2) and high (×4-×10) magnifications
(Figures 1 and 2, A).
Histological Analysis
The brain was fixed in phosphate-buffered 4% paraformaldehyde.
Histological coronal brain sections were stained with hematoxylin and
eosin (HE) by using a standard procedure or immunostained by usingxpressing melanoma cells visualized by fluorescence imaging and
nial surface, the caudal surface, and three coronal sections of the
ate the positions of the coronal brain sections. Arrow indicates the
cells at the injection site (left panel), in the lateral ventricles (middle
C) GFP-stained histological brain sections showing D-12 cells in the
e midbrain (middle panel), and the brain stem and cerebellum (right
Figure 3. GFP-stained histological brain sections showing mela-
noma lesions resulting from passive transport of tumor cells
through the cerebrospinal fluid. (A) R-18 cells within the two lateral
ventricles and the third ventricle (upper panels), and within the
fourth ventricle (lower panels). (B) R-18 cells within the folds on the
surface of the cerebellum. High-magnification images show areas
indicated by squares in the low-magnification images.
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polyclonal antibody or an anti-CD31 rabbit polyclonal antibody
(Abcam, Cambridge, United Kingdom) was used as primary antibody
to detect tumor cells or endothelial cells respectively. Diaminoben-
zidine was used as chromogen, and hematoxylin was used for
counterstaining.
Statistical Analysis
Comparisons of data were carried out by one-way analysis of
variance followed by Bonferroni’s test. The Kolmogorov-Smirnov
method and the Levene’s method were used to verify that the data
complied with the conditions of normality and equal variance.
Probability values of P b .05, determined from two-sided tests, were
considered significant. The statistical analysis was carried out with
SigmaStat statistical software.
Results and Discussion
Multiple Brain Lesions following Intracerebral Inoculation of
Melanoma Cells
To study melanoma cell migration within the brain, GFP-expres-
sing A-07, D-12, R-18, and U-25 cells were injected stereotactically
into the right cerebral hemisphere of nude mice. Clinical symptoms
of intracranial tumor growth were evident within 2 to 5 weeks, and
the intracranial growth pattern was evaluated by fluorescence imaging
or by GFP immunohistochemistry. Figure 2, A shows examples of
fluorescence images of a brain obtained 4 weeks after injection.
GFP-expressing melanoma cells were present at the injection site, on
the cranial and caudal brain surfaces, and in coronal brain sections
anterior and posterior to the injection site. Similar patterns of
multiple melanoma lesions were observed in GFP-stained histological
sections, as illustrated in Figure 2, B and C. Histological sections
revealed melanoma lesions located in the injection site (Figure 2, B,
left panel), in the ventricles (Figure 2, B, middle panel), in areas
between different brain compartments (Figure 2, B, right panel), and
in the leptomeningeal lining of various brain regions, including the
cerebrum, midbrain, brain stem, and cerebellum (Figure 2c).
Because the cells were injected into one well-defined intracerebral
site, the observed pattern of multiple melanoma lesions involving
brain compartments far from the injection site shows that the
melanoma cells were able to migrate across substantial distances
within the brain. Moreover, melanoma lesions were frequently
located in the ventricles or in the leptomeninges, thus suggesting that
the melanoma cells used these brain compartments as transport
routes. The A-07, D-12, R-18, and U-25 cell lines were all established
from subcutaneous metastases [13], and previous studies have
demonstrated that human melanoma cell lines established from
subcutaneous or lymph node metastases produce metastases mainly in
the meninges and ventricles following intra-arterial injection [17,18].
Furthermore, meningeal involvement has been observed in 7% to
23% of patients with melanoma brain metastases and was identified
as an important negative prognostic factor in multiple clinical studies
[6,7,19,20].
Passive Transport of Melanoma Cells via the Flow of
Cerebrospinal Fluid in the Meninges and Ventricles
In mice showing intraventricular tumor growth, melanoma lesions
were observed within multiple intraventricular spaces. This is
illustrated in Figure 3, A showing intraventricular melanoma lesions
within the two lateral ventricles, the third ventricle, and the fourthventricle. Furthermore, leptomeningeal tumor deposits were fre-
quently observed within the characteristic folds on the surface of the
cerebellum (Figure 3, B). The interconnected ventricular spaces and
the subarachnoid spaces within the meninges are filled with
cerebrospinal fluid (CSF), and it is well recognized that tumor cells
can spread through these spaces by passive transport via CSF flow
[21]. Thus, in patients with leptomeningeal involvement, tumor
deposits are frequently observed in areas characterized by slow CSF
flow, including the cerebral basal cisterns, the cauda equina, and the
folded surface of the cerebellum [22]. The melanoma lesions observed
within the ventricular system and within the folds on the surface of
the cerebellum in the present study were thus in accordance with
previous studies and suggest that passive transport of melanoma cells
via CSF flow in the meninges and ventricles is an important transport
route for melanoma cells within the brain.
Figure 4. Fluorescence images showing migration of GFP-expres-
sing melanoma cells along leptomeningeal blood vessels on the
brain surface. (A) D-12 cells migrating along multiple blood vessels
(arrows) away from a larger tumor lesion in the leptomeninges. (B)
D-12 cells migrating along a blood vessel (arrow) on the caudal
brain surface. (C) R-18 cells migrating along a blood vessel on the
cranial brain surface. Blood vessels are visible in the fluorescence
images because of the negative contrast of the red blood cells.
High-magnification images show areas indicated by squares in the
low-magnification images. Right panels of (C) show a schematic
illustration of the high-resolution fluorescence images and show
blood vessels in red and GFP-expressing tumor cells in green.
Figure 5. Melanoma cell invasion of the brain parenchyma along
blood vessels entering the brain from the leptomeninges. (A)
Fluorescence images showing GFP-expressing U-25 cells in a
coronal brain section. Arrow indicates blood vessel. High-magni-
fication image shows area indicated by a square in the
low-magnification image. (B) Histological brain sections showing
GFP-expressing D-12 cells. High-resolution images show a
GFP-stained, an HE-stained, and a CD31-stained histological
section of the area indicated by a square in the low-resolution
GFP-stained section.
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and Parenchymal Blood Vessels
High-resolution fluorescence images revealed that melanoma cells
migrated actively along leptomeningeal blood vessels on the brainsurface. Three different examples are presented in Figure 4. Figure 4,
A shows melanoma cell migration along multiple leptomeningeal
blood vessels leading away from a larger lesion in the leptomeninges;
Figure 4, B shows melanoma cell migration along a blood vessel on
the caudal brain surface; and Figure 4, C shows melanoma cell
migration along a blood vessel on the cranial brain surface.
Furthermore, melanoma cells also migrated along blood vessels
within the brain parenchyma. This is illustrated in Figure 5 showing
fluorescence images of a coronal brain section (Figure 5, A) and
GFP-stained, HE-stained, and CD31-stained histological brain
sections (Figure 5, B) showing melanoma cells migrating along
blood vessels entering the brain parenchyma from the leptomeninges.
Our data are consistent with previous studies demonstrating
melanoma cell migration along blood vessels within the brain
[8,9,11], and moreover, they show that melanoma cells are able to
migrate actively along blood vessels across substantial distances.
Active Migration of Melanoma Cells along the Surfaces
Separating Different Brain Compartments
GFP-stained histological sections revealed multiple small colonies
of melanoma cells located in the surfaces separating different brain
compartments. Figure 6, A shows an example of two small melanoma
cell colonies along the surfaces separating the right and left cerebral
hemispheres. Interestingly, they are located between two larger lesions
Figure 6. GFP-stained histological brain sections showing GFP-expressing melanoma cells migrating along the surfaces separating
different brain compartments. (A) R-18 cells migrating between the right and left cerebral hemisphere. (B) R-18 cells migrating between
the midbrain and the hippocampal region of the right cerebral hemisphere. (C) R-18 cells migrating between the left cerebral hemisphere
and the midbrain. High-magnification images show areas indicated by squares in the low-magnification images.
216 Intracranial Melanoma Cell Migration Simonsen et al. Translational Oncology Vol. 9, No. 3, 2016on the cranial and caudal brain surfaces. Figure 6, B and C shows
similar examples of melanoma cells located between the midbrain and
the right cerebral hemisphere (Figure 6, B) and between the midbrain
and the left cerebral hemisphere (Figure 6, C). These images suggest
that the melanoma cells migrated actively along the surfaces
separating different brain compartments. To the best of our
knowledge, it has not been previously reported that melanoma cells
can migrate between all these different brain compartments.
Differences in Aggressiveness and Intracranial Spread between
Melanoma Lines
The melanoma lines differed significantly in aggressiveness after
intracerebral cell inoculation. The mean time from inoculation to
euthanization of the host mouse varied from ~17 to ~26 days
(Figure 7, A) and was significantly longer for the D-12 and R-18 lines
than for the A-07 and U-25 lines (P b .001). Intracerebral tumors that
spread by passive transport via CSF flow developed multiple
intraventricular lesions, and this route of intracranial spread was
used frequently by R-18 cells and rarely by A-07 and U-25 cells
(Figure 7, B). Active migration of tumor cells along the surfaces of
vessels and brain compartments resulted in multiple meningeal
lesions, and A-07 and U-25 cells spread primarily by this route,
whereas this route was used less frequently by D-12 and R-18 cells(Figure 7, C). Taken together, these observations suggest that highly
aggressive intracerebral melanoma lesions have cells with elevated
capability to migrate along tissue surfaces.
Differences in Aggressiveness between Intracerebral and
Intradermal Melanoma Lesions
The aggressiveness of A-07, D-12, R-18, and U-25 tumors
transplanted to intradermal sites in female BALB/c nu/nu mice has
been studied extensively in our laboratory. To compare intracerebral
tumors with intradermal tumors, some results from a recent study of
intradermal tumors are reproduced in Figure 7, D–F [23]. At the
intradermal site, the four lines differed significantly in tumor growth rate
(P b .05), and A-07 tumors showed the highest growth rate (i.e., the
shortest volume doubling time), whereas U-25 tumors showed the lowest
growth rate (i.e., the longest volume doubling time; Figure 7, D). Also,
the angiogenic activity differed significantly among the four lines (Pb .05,
Figure 7, E), and there was a strong correlation between tumor growth
rate and tumor-induced angiogenic activity (P b .001). Furthermore,
tumor cell invasiveness measured in vitro in Matrigel invasion chambers
differed among the lines and was significantly higher for A-07 and D-12
cells than for R-18 and U-25 cells (P b .01, Figure 7, F).
Thus, A-07 cells were highly aggressive at the intracerebral as well
as the intradermal site, whereas U-25 cells were highly aggressive at
Figure 7. Aggressiveness of experimental intracerebral and intradermal melanoma lesions. (A) Mouse survival time following intracerebral
inoculation of melanoma cells. Columns and bars represent mean ± SE of 20 mice. (B) Fraction of intracerebral melanomas showing
metastatic spread by passive transport of tumor cells via cerebrospinal fluid flow (n = 20). (C) Fraction of intracerebral melanomas
showing metastatic spread by active migration of tumor cells along tissue surfaces (n = 20). (D) Volume doubling time of intradermal
melanomas. Columns and bars represent mean ± SE of 20 tumors. (E) Angiogenic potential determined by inoculating 1.0 × 106
melanoma cells intradermally and counting the tumor-oriented blood vessels 7 days later. Columns and bars represent mean ± SE of 20
tumors. (F) Relative invasiveness of melanoma cells measured in vitro in Matrigel invasion chambers by using Z-98 melanoma cells as a
reference. Columns and bars represent mean ± SE of six experiments. The data in panels (D), (E), and (F) were reproduced from a
previous publication, and experimental details are described in that publication [23].
Translational Oncology Vol. 9, No. 3, 2016 Intracranial Melanoma Cell Migration Simonsen et al. 217the intracerebral site and poorly aggressive at the intradermal site.
Furthermore, the aggressiveness at the intradermal site was associatedwith
the angiogenic potential of the tumor cells, whereas the aggressiveness at
the intracerebral site was associated with the capability of the tumor cells
to migrate along tissue surfaces. Interestingly, there was no correlation
between tumor cell migration in the brain and tumor cell invasiveness in
vitro, suggesting that these properties of melanoma cells are governed by
different mechanisms. Taken together, our observations imply that there
is no correlation between the aggressiveness of melanoma lesions in the
brain and in the dermis. This finding may have significant implications
for the treatment of melanoma patients with advanced disease. These
patients may have multiple cutaneous and brain metastases, and
treatments that may be efficient against cutaneous metastases may not
necessarily be efficient against brain metastases and vice versa.
Consequently, efficient treatment of advanced melanoma may require
therapeutic strategies combining different treatment modalities or
different anticancer agents. Studies of A-07, D-12, R-18, and U-25
tumors suggest that treatment strategies targeting angiogenesis may be
potentially useful against cutaneous metastases, whereas treatment of
metastases in the brain may require treatment strategies targeting active
tumor cell migration.Conclusions
Melanoma cells are highly motile within the brain, and they can
migrate to different brain regions by passive transport via CSF flow in
the ventricles, by active migration along leptomeningeal and
parenchymal blood vessels, and by active migration along the surfaces
of the brain compartments. The different transport modes were
observed in all four melanoma lines studied here, suggesting that these
transport modes are common in melanoma. Consequently, intracra-
nial migration of tumor cells may contribute significantly to the high
incidence of multiple brain metastases in melanoma patients. Once
melanoma cells have reached the brain, new lesions within multiple
brain regions may continue to develop even in a situation where the
systemic disease is controlled.
Efficient treatment strategies for melanoma patients with advanced
disease may need to target cutaneous lesions as well as lesions residing
within multiple regions of the brain and, hence, lesions having
substantially different microenvironments [17,18]. Because the
response of melanoma lesions to treatment is greatly affected by the
tumor microenvironment [24,25], the development of efficient
treatment strategies for melanoma patients with multiple cutaneous
and brain metastases may be an immense challenge.
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